Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) – Investment analysts at SVB Leerink upped their FY2026 EPS estimates for Cullinan Oncology in a research note issued to investors on Thursday, March 17th. SVB Leerink analyst A. Berens now expects that the company will post earnings per share of $2.82 for the year, up from their […]
Cullinan Oncology (NASDAQ:CGEM – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.24), MarketWatch Earnings reports. CGEM stock traded up $0.52 during midday trading on Friday, hitting $13.33. The stock had a trading volume of 726,025 shares, […]
Posted on 7440
Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing.
This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures.
Dr. Samuel Cohen, Chief Executive Officer of Wren, commented: “This support from both our existing as well as our new shareholders will accelerate the advancement of our two lead small molecule programs towards the clinic for the potential treatment of Alzheimer’s disease and various synucleinopathies including Parkinson’s disease.”
Press release content from Business Wire. The AP news staff was not involved in its creation.
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
January 25, 2021 GMT
CAMBRIDGE, United Kingdom (BUSINESS WIRE) Jan 25, 2021
Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing.
This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures.
Cullinan Management Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 per share. All shares are being offered by Cullinan Management. The gross proceeds to Cullinan Management from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $249.9 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,785,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market un